3 results
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…
Primary Objective:* Assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions as indicated by proportion of population reporting with…
Divergent Low Level Laser Therapy as novel treatment for oral mucositis in pediatric cancer patients
Primary Objective: - To assess the effect of divergent LLLT on the number of days of mucositis > grade 1Secondary Objective(s): - To assess the effect of divergent LLLT on the severity of mucositis - To assess the effect of divergent LLLT on…